Product

Pritelivir + Moxifloxacin

1 clinical trial

1 indication

Indication

Herpes Simplex Virus Infection

Clinical trial

A Double-blind, Single-center, Randomized, Placebo- and Positive-controlled, Parallel-group Trial With a Nested Crossover Part on the Electrocardiographic Effects 100 and 400 mg Pritelivir Per Day in Healthy Subjects: a Thorough QT/QTc Trial

Status: Completed, Estimated PCD: 2023-05-18